2021年10月11日讯 /生物谷BIOON/ --安进（Amgen）近日宣布，美国食品和药物管理局（FDA）已批准Repatha（瑞百安®，通用名：通用名 ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...